BCMA-Targeting Agents in the Treatment of Multiple Myeloma: Right Patient, Right Time

Sagar Lonial, MD, FACP, highlights a novel treatment option available for a 57-year-old man whose disease progresses after 3 prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

The rationale for treating relapsed/refractory multiple myeloma with belantamab mafodotin, and studies investigating the drug’s potential in earlier treatment settings.

Karen L. Klugo, MD, describes what’s unique in terms of patient response to belantamab mafodotin as treatment for relapsed/refractory multiple myeloma and risk of ocular disease.

Natalie Callander, MD, presents the profile of a female patient with relapsed/refractory multiple myeloma who receives belantamab mafodotin and develops keratopathy.

Variables that impact treatment decisions for relapsed/refractory multiple myeloma.

What to know in terms of dosing belantamab mafodotin treatment in patients with relapsed/refractory multiple myeloma.

Recommendations for managing ocular toxicities associated with belantamab mafodotin when used as treatment for relapsed/refractory multiple myeloma.

Implications for treating patients with relapsed/refractory multiple myeloma with CAR T cells vs antibody-drug conjugates.

An overview of novel bispecific therapies under development in relapsed/refractory multiple myeloma.

Current combination approaches, including BCMA-targeting agents like belantamab mafodotin, being explored to address treatment gaps in relapsed/refractory multiple myeloma.

Considerations for optimizing treatment with BCMA-targeting agents for patients with relapsed/refractory multiple myeloma moving forward.